vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and BlackSky Technology Inc. (BKSY). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $35.2M, roughly 1.3× BlackSky Technology Inc.). BlackSky Technology Inc. runs the higher net margin — -2.5% vs -23.3%, a 20.8% gap on every dollar of revenue. On growth, BlackSky Technology Inc. posted the faster year-over-year revenue change (15.9% vs 7.0%). Over the past eight quarters, BlackSky Technology Inc.'s revenue compounded faster (20.5% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

BlackSky Technology Inc. is a leading geospatial intelligence provider operating a constellation of high-revisit small Earth observation satellites. It delivers real-time satellite imagery, advanced data analytics, and dynamic monitoring solutions to government, defense, critical infrastructure, and commercial clients globally to support data-driven operational decision-making.

AMRN vs BKSY — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.3× larger
AMRN
$45.1M
$35.2M
BKSY
Growing faster (revenue YoY)
BKSY
BKSY
+8.9% gap
BKSY
15.9%
7.0%
AMRN
Higher net margin
BKSY
BKSY
20.8% more per $
BKSY
-2.5%
-23.3%
AMRN
Faster 2-yr revenue CAGR
BKSY
BKSY
Annualised
BKSY
20.5%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
BKSY
BKSY
Revenue
$45.1M
$35.2M
Net Profit
$-10.5M
$-868.0K
Gross Margin
Operating Margin
35.5%
-11.8%
Net Margin
-23.3%
-2.5%
Revenue YoY
7.0%
15.9%
Net Profit YoY
33.0%
95.5%
EPS (diluted)
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
BKSY
BKSY
Q1 26
$45.1M
Q4 25
$49.2M
$35.2M
Q3 25
$49.7M
$19.6M
Q2 25
$72.7M
$22.2M
Q1 25
$42.0M
$29.5M
Q4 24
$62.3M
$30.4M
Q3 24
$42.3M
$22.5M
Q2 24
$67.5M
$24.9M
Net Profit
AMRN
AMRN
BKSY
BKSY
Q1 26
$-10.5M
Q4 25
$-1.2M
$-868.0K
Q3 25
$-7.7M
$-15.3M
Q2 25
$-14.1M
$-41.2M
Q1 25
$-15.7M
$-12.8M
Q4 24
$-48.6M
$-19.4M
Q3 24
$-25.1M
$-12.6M
Q2 24
$1.5M
$-9.4M
Gross Margin
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
BKSY
BKSY
Q1 26
35.5%
Q4 25
-12.9%
-11.8%
Q3 25
-22.4%
-85.8%
Q2 25
-22.0%
-62.8%
Q1 25
-39.9%
-40.5%
Q4 24
-84.3%
-20.0%
Q3 24
-59.5%
-58.7%
Q2 24
-0.8%
-47.0%
Net Margin
AMRN
AMRN
BKSY
BKSY
Q1 26
-23.3%
Q4 25
-2.5%
-2.5%
Q3 25
-15.6%
-78.2%
Q2 25
-19.4%
-185.8%
Q1 25
-37.4%
-43.4%
Q4 24
-78.0%
-63.9%
Q3 24
-59.4%
-55.8%
Q2 24
2.3%
-37.7%
EPS (diluted)
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
$0.00
$0.04
Q3 25
$-0.02
$-0.44
Q2 25
$-0.03
$-1.27
Q1 25
$-0.04
$-0.42
Q4 24
$-0.12
$-0.61
Q3 24
$-0.06
$-0.66
Q2 24
$0.00
$-0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
BKSY
BKSY
Cash + ST InvestmentsLiquidity on hand
$307.8M
$124.5M
Total DebtLower is stronger
$201.1M
Stockholders' EquityBook value
$94.9M
Total Assets
$645.8M
$386.2M
Debt / EquityLower = less leverage
2.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
BKSY
BKSY
Q1 26
$307.8M
Q4 25
$302.6M
$124.5M
Q3 25
$286.6M
$146.5M
Q2 25
$298.7M
$93.8M
Q1 25
$281.8M
$75.8M
Q4 24
$294.2M
$52.5M
Q3 24
$305.7M
$63.2M
Q2 24
$306.7M
$41.2M
Total Debt
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
$201.1M
Q3 25
$195.1M
Q2 25
$122.5M
Q1 25
$115.3M
Q4 24
$107.7M
Q3 24
$98.8M
Q2 24
$108.6M
Stockholders' Equity
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
$459.3M
$94.9M
Q3 25
$458.9M
$91.1M
Q2 25
$464.9M
$86.6M
Q1 25
$473.7M
$88.8M
Q4 24
$486.2M
$94.0M
Q3 24
$531.4M
$110.3M
Q2 24
$551.9M
$76.5M
Total Assets
AMRN
AMRN
BKSY
BKSY
Q1 26
$645.8M
Q4 25
$670.8M
$386.2M
Q3 25
$659.8M
$380.9M
Q2 25
$670.1M
$310.8M
Q1 25
$655.7M
$284.9M
Q4 24
$685.3M
$254.1M
Q3 24
$750.6M
$245.5M
Q2 24
$799.9M
$224.3M
Debt / Equity
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
2.12×
Q3 25
2.14×
Q2 25
1.41×
Q1 25
1.30×
Q4 24
1.15×
Q3 24
0.90×
Q2 24
1.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
BKSY
BKSY
Operating Cash FlowLast quarter
$-9.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
$15.3M
$-9.3M
Q3 25
$-12.7M
$-39.0M
Q2 25
$16.6M
$-7.3M
Q1 25
$-12.5M
$27.2M
Q4 24
$-13.3M
$-1.8M
Q3 24
$-2.4M
$1.0M
Q2 24
$-2.7M
$-1.8M
Cash Conversion
AMRN
AMRN
BKSY
BKSY
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

BKSY
BKSY

Segment breakdown not available.

Related Comparisons